期刊
CANCERS
卷 15, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/cancers15041077
关键词
malignant peripheral nerve sheath tumor; neurofibromatosis type 1; plexiform neurofibroma; atypical neurofibromatous neoplasm of unknown biological potential; molecular diagnosis; target therapy
类别
Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma with limited treatment options and a poor prognosis. This review summarizes the current understanding of MPNST pathogenesis and the latest advancements in diagnosis, treatment, and targeted therapies. The challenges and prospects for MPNST management are also discussed.
Simple Summary Malignant peripheral nerve sheath tumor (MPNST) is a soft tissue sarcoma with limited therapeutic interventions and a poor prognosis. This review summarized the current understanding of the pathogenic mechanisms behind MPNST and the latest concepts in clinical management from diagnosis to therapeutic intervention. Additionally, the developments in molecular diagnosis and targeted therapies for MPNST are highlighted. It concluded with the challenges and prospects of MPNST management. Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma with limited therapeutic options and a poor prognosis. Although neurofibromatosis type 1 (NF1) and radiation exposure have been identified as risk factors for MPNST, the genetic and molecular mechanisms underlying MPNST pathogenesis have only lately been roughly elucidated. Plexiform neurofibroma (PN) and atypical neurofibromatous neoplasm of unknown biological potential (ANNUBP) are novel concepts of MPNST precancerous lesions, which revealed sequential mutations in MPNST development. This review summarized the current understanding of MPNST and the latest consensus from its diagnosis to treatment, with highlights on molecular biomarkers and targeted therapies. Additionally, we discussed the current challenges and prospects for MPNST management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据